BBOT Short Volume
BridgeBio Oncology Therapeutics Inc. (BBOT) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $718.6M, listed on NASDAQ, employing roughly 62 people, carrying a beta of 0.22 to the broader market. BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Led by Eli Wallace, public since 2025-08-12.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-06-01
- Short Volume
- 60.9K
- Total Volume
- 72.9K
- Short %
- 83.56%
- 30-Day Avg Short %
- 57.39%
Showing 30 days of FINRA short volume data for BridgeBio Oncology Therapeutics Inc..
Learn how short volume is reported and how to read the data →
Frequently asked BBOT short volume questions
- What is the daily BBOT short volume?
- As of Jun 1, 2026, BridgeBio Oncology Therapeutics Inc. (BBOT) short volume is 60.9K shares against 72.9K total reported volume, or 83.56% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is BBOT short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does BBOT short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.